Marien-Hospital WeselProhomine - Logo

Aktuelle wissenschaftliche Publikationen in 2015 und 2016, u. a. zu Krebs- und Lebererkrankungen

Radhakrishnan P, Ruh N, Harnoss JM, Kiss J, Mollenhauer M, Scherr AL, Platzer LK, Schmidt T, Podar K, Opferman JT, Weitz J, Schulze-Bergkamen H, Koehler BC, Ulrich A, Schneider M. Prolyl hydroxylase 3 attenuates MCL-1-mediated ATP production to suppress the metastatic potential of colorectal cancer cells. Cancer Res. 2016 Feb 26.

Bashari MH, Fan F, Vallet S, Sattler M, Arn M, Luckner-Minden C, Schulze-Bergkamen H, Zörnig I, Marme F, Schneeweiss A, Cardone MH, Opferman JT, Jäger D, Podar K. Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Res. 2016 Feb 26;18(1):26.

Flanagan L, Meyer M, Fay J, Curry S, Bacon O, Duessmann H, John K, Boland KC, McNamara DA, Kay EW, Bantel H, Schulze-Bergkamen H, Prehn JH. Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach. Cell Death Dis. 2016 Feb 4

Koehler BC, Jassowicz A, Scherr AL, Lorenz S, Radhakrishnan P, Kautz N, Elssner C, Weiss J, Jaeger D, Schneider M, Schulze-Bergkamen H. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. BMC Cancer. 2015 Nov 19;15:919

Pfeiffenberger J, Mogler C, Gotthardt DN, Schulze-Bergkamen H, Litwin T, Reuner U, Hefter H, Huster D, Schemmer P, Czlonkowska A, Schirmacher P, Stremmel W, Cassiman D, Weiss KH. Hepatobiliary malignancies in Wilson disease. Liver Int. 2015 May;35(5):1615.

Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Düber C, Lang H, Otto G, Wörns MA, Galle PR. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int. 2015 Feb;35(2):591-600.

Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Wörns MA, Galle PR, Schulze-Bergkamen H. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients. J Clin Gastroenterol. 2015 May-Jun;49(5):438-47

Weitere ausgewählte Publikationen als Erst- oder Letztautor

Hofmann H, von Haken R, Werner J, Kortes N, Bergmann F, Schemmer P, Jäger D, Radeleff B, Schulze-Bergkamen H. Unresectable isolated hepatic metastases from solid pseudopapillary neoplasm of the pancreas: a case report of chemosaturation with high-dose melphalan. Pancreatology. 2014 Nov-Dec;14(6):546-9

Koehler BC, Jaeger D, Schulze-Bergkamen H. Targeting cell death signaling in colorectal cancer – current strategies and future perspectives. World Journal of Gastroenterology 2014;  20(8):1923-34.

Welte S, Urbanik T, Koehler BC, Lorenzo Bermejo J, Pinna F, Weiss KH, Schemmer P, Jaeger D, Longerich T, Breuhahn K, Schulze-Bergkamen H. Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma. PLoS One. 2014; 9(10):e110591.

Koehler BC, Scherr AL, Lorenz S, Elssner C, Kautz N, Welte S, Jaeger D, Urbanik T, Schulze-Bergkamen H. Pan-Bcl-2 inhibitor Obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PloS One. 2014; 9(9):e106571.

Urbanik T, Koehler BC, Wolpert L, Elssner C, Scherr AL, Longerich T, Kautz N, Welte S, Hoevelmeyer N, Jaeger D, Waisman A, Schulze-Bergkamen H. CYLD deletion triggers nuclear factor-kB-signaling and increases cell death resistance in murine hepatocytes. World J  Gastroenterol. 2014; 20(45):17049-64.

Koehler BC, Scherr AL, Lorenz S, Urbanik T, Kautz N, Elssner C, Welte S, Jäger D, Schulze-Bergkamen H. Beyond cell death – Antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. PLOS One 2013; 8(10):e76446.

Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hövelmeyer N, Hahn M, Schuchmann M, Jäger D, Waisman A, Wörns MA, Schulze-Bergkamen H. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice. Journal of Hepatology 2012; 57:995-1003. Editorial: Gautheron J, Luedde T. A novel player in inflammation and cancer: The deubiquitinase CYLD controls HCC development. Journal of Hepatology 2012; 57(5):937-9.

Weber A, Boger RJ, Vick B, Urbanik T, Haybaeck J, Zoller S, Teufel A, Krammer PH, Opferman JT, Galle PR, Heikenwalder M, Schuchmann M, Schulze-Bergkamen H. Hepatocyte-specific deletion of the anti-apoptotic protein Mcl-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 2010; 51(4):1226-1236. Editorial: Jost PJ, Kaufmann T. Cancer caused by too much apoptosis – an intriguing contradiction? Hepatology 2010; 51:1110-1112

Vick B, Weber A, Urbanik T, Krammer PH, Opferman JT, Schuchmann M, Galle PR, Schulze-Bergkamen H. Knock-out of Myeloid cell leukaemia-1 induces profound liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology 2009; 49(2):627-36.

Schulze-Bergkamen H, Weinmann A, Möhler M, Siebler J, Galle PR. Novel ways to sensitize gastrointestinal cancer to apoptosis. Gut 2009; 58(7):1010-24.

Schulze-Bergkamen H, Brenner D, Krueger A, Suess D, Fas SC, Frey CR, Dax A, Zink D, Büchler P, Müller M, Krammer PH. Hepatocyte Growth Factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Hepatology 2004; 39:645-654.

Schulze-Bergkamen H, Untergasser A, Dax A, Vogel H, Büchler P, Klar E, Lehnert T, Friess H, Büchler MW, Kirschfink M, Stremmel W, Krammer PH, Müller M, Protzer U. Primary human hepatocytes – a valuable tool for investigation of apoptosis and hepatitis B virus infection. Journal of Hepatology 2003; 38(6):736-744.